nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2015 | Original Article – Clinical Oncology

Poor graft function can be durably and safely improved by CD34⁺-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation

verfasst von: Sebastian P. Haen, Michael Schumm, Christoph Faul, Lothar Kanz, Wolfgang A. Bethge, Wichard Vogel

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Insufficient production of leukocytes, thrombocytes and erythrocytes after allogeneic peripheral blood stem cell transplantation (PBSCT) represents a life-threatening complication.

Methods

In 20 adult patients with poor graft function (PGF defined as transfusion-dependent platelet counts <20,000/µl, or leukocytes <1500/µl, or transfusion-dependent anemia) and variable causes of PGF after allogeneic PBSCT, immunomagnetically selected CD34⁺ stem cell boosts (SCB) from matched unrelated (n = 8), mismatched unrelated (n = 11) or haploidentical (n = 1) donors were applied without prior conditioning.

Results

Patients received a median of 4.6 × 10⁶ CD34⁺ cells per kilogram bodyweight (1.9–9.1 × 10⁶) and low T cell numbers (median 0.2 × 10⁴, range 0.04–0.6 × 10⁴). All patients showed responses in at least one hematopoietic lineage. Engraftment for platelets, leukocytes and hemoglobin was 88, 88 and 100 % after a median of 14, 13 and 18 days, respectively. With regard to the complete cohort, 90 % (n = 18) showed an increase in platelets (median 76,500/µl, range −7000 to 223,000/µl), 95 % (n = 19) had an increase in leukocytes (median 3110/µl, range 150–13,740/µl) and 90 % (n = 18) improved with regard to hemoglobin (median 1.9 g/dl, range −0.9 to 5.1 g/dl). Due to effective T cell depletion, only one patient developed graft versus host disease (GvHD, grade III) after SCB. Patients were followed for a median of 7.5 months (1–74 months) with 11 patients being alive and disease free with normalized peripheral blood counts at the end of follow-up.

Conclusions

CD34⁺-selected SCB are safe and effective and can durably improve PGF even in patients receiving grafts from unrelated matched or mismatched donors with low incidence of GvHD.

Askaa B, Fischer-Nielsen A, Vindelov L, Haastrup EK, Sengelov H (2014) Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning. Bone Marrow Transplant 49:720–721. doi:10.1038/bmt.2014.5 CrossRefPubMed

Bittencourt H, Rocha V, Filion A, Ionescu I, Herr AL, Garnier F, Ades L, Esperou H, Devergie A, Ribaud P, Socie G, Gluckman E (2005) Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplant 36:431–435CrossRefPubMed

Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407–414CrossRefPubMed

Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, Locatelli F, Falda M (2007) Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 9:102–107CrossRefPubMed

Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, Heller G, Hsu KC, Perales MA, van den Brink MR, Young JW, Prockop SE, Collins NH, O’Reilly RJ, Boulad F (2007) Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 13:1313–1323CrossRefPubMed

Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, Buzyn A, Lioure B, Bordigoni P, Fegueux N, Tanguy ML, Vernant JP, Gluckman E, Socie G (2000) Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol 111:292–302CrossRefPubMed

Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF (2007) Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 40:431–435CrossRefPubMed

Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarie C, Faucher C, Bacher U, Alchalby H, Stubig T, Wolschke C, Ayuk F, Reckhaus ML, Blaise D, Kroger N (2013) CD34-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant 20:382–386. doi:10.1016/j.bbmt.2013.11.034 CrossRefPubMed

Kopp HG, Wirths S, Faul C, Bethge W, Scheding S, Brugger W, Kanz L, Vogel W (2010) Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors. J Cancer Res Clin Oncol 136:1921–1927. doi:10.1007/s00432-010-0851-6 CrossRefPubMed

Lagadinou ED, Marangos M, Liga M, Panos G, Tzouvara E, Dimitroulia E, Tiniakou M, Tsakris A, Zoumbos N, Spyridonidis A (2010) Human herpesvirus 6-related pure red cell aplasia, secondary graft failure, and clinical severe immune suppression after allogeneic hematopoietic cell transplantation successfully treated with foscarnet. Transpl Infect Dis 12:437–440. doi:10.1111/j.1399-3062.2010.00515.x CrossRefPubMed

Lang P, Handgretinger R, Niethammer D, Schlegel PG, Schumm M, Greil J, Bader P, Engel C, Scheel-Walter H, Eyrich M, Klingebiel T (2003) Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood 101:1630–1636CrossRefPubMed

Larocca A, Piaggio G, Podesta M, Pitto A, Bruno B, Di GC, Gualandi F, Occhini D, Raiola AM, Dominietto A, Bregante S, Lamparelli T, Tedone E, Oneto R, Frassoni F, Van Lint MT, Pogliani E, Bacigalupo A (2006) Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 91:935–940PubMed

Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, Marks DI, van Rood JJ, Scaradavou A, Horowitz MM (2004) Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351:2265–2275CrossRefPubMed

Oyekunle A, Koehl U, Schieder H, Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingebiel T, Sputtek A, Zander A, Kroger N (2006) CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation. Cytotherapy 8:375–380CrossRefPubMed

Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, O’Reilly RJ, Soiffer RJ (2012) Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 30:3194–3201. doi:10.1200/JCO.2012.41.7071 PubMedCentralCrossRefPubMed

Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, Witte TD, Farge-Bancel D, Gaspar B, Marsh J, Mohty M, Peters C, Tichelli A, Velardi A, de Elvira CR, Falkenburg F, Sureda A, Madrigal A (2012) The EBMT activity survey: 1990–2010. Bone Marrow Transplant 47:906–923. doi:10.1038/bmt.2012.66 CrossRefPubMed

Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T, Storer B, Mickelson E, Smith A, Anasetti C (2001) Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345:1794–1800CrossRefPubMed

Remberger M, Ringden O, Ljungman P, Hagglund H, Winiarski J, Lonnqvist B, Aschan J (1998) Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 22:73–78CrossRefPubMed

Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E (2008) Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14:859–866. doi:10.1016/j.bbmt.2008.05.005 PubMedCentralCrossRefPubMed

Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, Bredeson CN, Gupta V, Maziarz RT, Hale GA, Litzow MR, Logan B, Bornhauser M, Giller RH, Isola L, Marks DI, Rizzo JD, Pasquini MC (2010) Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant 16:1099–1106. doi:10.1016/j.bbmt.2010.02.013 PubMedCentralCrossRefPubMed

Schumm M, Lang P, Taylor G, Kuci S, Klingebiel T, Buhring HJ, Geiselhart A, Niethammer D, Handgretinger R (1999) Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J Hematother 8:209–218CrossRefPubMed

Slatter MA, Bhattacharya A, Abinun M, Flood TJ, Cant AJ, Gennery AR (2005) Outcome of boost haemopoietic stem cell transplant for decreased donor chimerism or graft dysfunction in primary immunodeficiency. Bone Marrow Transplant 35:683–689CrossRefPubMed

Stasia A, Ghiso A, Galaverna F, Raiola AM, Gualandi F, Luchetti S, Pozzi S, Varaldo R, Lamparelli T, Bregante S, Van Lint MT, Di GC, Bacigalupo A (2014) CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20:1440–1443. doi:10.1016/j.bbmt.2014.05.016 CrossRefPubMed

Torok-Storb B, Holberg L, Mielcarek M (2000) Mechanisms of poor marrow function and late graft failure. In: Atkinson K (ed) Clinical bone marrow and blood stem cell transplantation. Cambridge University Press, Cambridge, pp 67–73

Wolff SN (2002) Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 29:545–552CrossRefPubMed

Woolfrey A, Anasetti C (1999) Allogeneic hematopoietic stem-cell engraftment and graft failure. Pediatr Transplant 3(Suppl 1):35–40CrossRefPubMed

Titel: Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation
verfasst von: Sebastian P. Haen
Michael Schumm
Christoph Faul
Lothar Kanz
Wolfgang A. Bethge
Wichard Vogel
Publikationsdatum: 01.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2027-x

Springer Medizin

Poor graft function can be durably and safely improved by CD34⁺-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation